Whilst the Government might be making (and subsequently reneging on) policy around prenatal care and IVF visits due to COVID, one company is actually making positive strides ahead. Medical data and technology company HeraMED (ASX: HMD) is readying themselves for a full commercial rollout of HeraCARE, their prenatal and foetal health monitoring system to expectant
Read More
With the rapid acceleration of telehealth solutions brought about by the pandemic, one company is uniquely servicing a key demographic- expectant mothers. Medtech HeraMED (ASX: HMD) is moving obstetric care into 2021 with their comprehensive digital health platform, HeraCARE and associated fetal and maternal heart rate monitor, HeraBEAT. The clinically validated tech allows for remote
Read More
Medical data and technology company HeraMED (ASX: HMD) has today announced a partnership to accelerate their mission to revolutionise maternal care. The Company has entered into a paid pilot with Obstetrix Medical Group, one of the largest clinical providers in the US for both women’s and children’s health. Obstetrix, an affiliate of US $2.2 billion
Read More